Med­lab ramps up

Pharmacy Daily - - News -

ASX LISTED cannabis and nan­ode­liv­ery sys­tem com­pany Med­lab has re­leased progress re­sults on its prod­uct de­vel­op­ment, in­clud­ing the suc­cess­ful com­ple­tion of stage 1 of its Nan­abis can­cer trial at Syd­ney’s Royal North Shore Hospi­tal.

For­mal ap­proval has been re­ceived from the In­de­pen­dent Data Safety Mon­i­tor­ing Board to pro­ceed to Stage 2 of the trial, fo­cus­ing again on safety along­side dosage es­ca­la­tion and tol­er­ance.

Other de­vel­op­ments in­clude Med­lab’s NanaBidi­alanti-emetic treat­ment which is about to com­mence a clin­i­cal trial for pa­tients with chemother­a­pyin­duced nau­sea, while a third an­nounce­ment re­lated to a trial of NanoS­tat, a nano-par­ti­cle spray of a statin.

Called NanoCelle, the sys­tem en­ables de­liv­ery of small doses and with the trial now com­pleted, re­sults will be avail­able in a month.

The com­pany is also un­der­tak­ing in­ter­na­tional ne­go­ti­a­tions to en­hance global mar­ket pen­e­tra­tion.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.